Opus Genetics, Inc. (NASDAQ:IRD) is among the 12 hot penny stocks to invest in right now. Piper Sandler initiated coverage on IRD with an “Overweight” rating and $7 price target. The company’s lead gene therapy program, OPGx-LCA5, aims to treat Leber congenital amaurosis type 5, a condition with no current treatments. Opus Genetics reported a widened net loss in Q3 2025, driven by changes in the fair value of warrants. Positive Phase 1/2 data for OPGx-LCA5 showed significant improvements in vision for pediatric patients. Opus Genetics completed a successful Type B Regenerative Medicine Advanced Therapy meeting with the FDA, enhancing the potential for accelerated regulatory approval. The company also completed a $23 million equity offering to support advancing clinical trials for OPGx-BEST1. Opus Genetics is dedicated to developing gene therapies to restore vision in patients with inherited retinal diseases. While IRD presents an investment opportunity, certain AI stocks may offer greater upside potential with less downside risk.

Read more at Yahoo Finance: Piper Sandler Initiates Coverage on Opus Genetics, Inc. (IRD) With “Overweight” Rating and $7 PT